{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T20:27:24Z","timestamp":1776371244198,"version":"3.51.2"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T00:00:00Z","timestamp":1737158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T00:00:00Z","timestamp":1737158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00280-024-04740-x","type":"journal-article","created":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T05:08:44Z","timestamp":1737176924000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Dihydropyrimidine enzyme activity and its effect on chemotherapy toxicity: importance of genetic testing"],"prefix":"10.1007","volume":"95","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-9755-6472","authenticated-orcid":false,"given":"Alexia","family":"Shamaei Zadeh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abby","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepali","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5583-0093","authenticated-orcid":false,"given":"John L.","family":"Villano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,18]]},"reference":[{"key":"4740_CR1","doi-asserted-by":"publisher","first-page":"181","DOI":"10.3816\/CCC.2004.n.018","volume":"4","author":"H Ezzeldin","year":"2004","unstructured":"Ezzeldin H, Diasio R (2004) Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration. Clin Colorectal Cancer 4:181\u2013189","journal-title":"Clin Colorectal Cancer"},{"key":"4740_CR2","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1517\/14740338.2010.511610","volume":"9","author":"SE Mikhail","year":"2010","unstructured":"Mikhail SE, Sun JF, Marshall JL (2010) Safety of capecitabine: a review. Exp Opin Drug Saf 9:831\u2013841","journal-title":"Exp Opin Drug Saf"},{"key":"4740_CR3","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1517\/14622416.3.4.485","volume":"3","author":"LK Mattison","year":"2002","unstructured":"Mattison LK, Soong R, Diasio RB (2002) Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics. Pharmacogenomics 3:485\u2013492","journal-title":"Pharmacogenomics"},{"key":"4740_CR4","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/1097-0142(19910801)68:3<499::AID-CNCR2820680309>3.0.CO;2-F","volume":"68","author":"BE Harris","year":"1991","unstructured":"Harris BE, Carpenter JT, Diasio RB (1991) Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome. Cancer 68:499\u2013501","journal-title":"Cancer"},{"key":"4740_CR5","doi-asserted-by":"crossref","unstructured":"Fidai SS, Sharma AE, Johnson DN et al (2018) Dihydropyrimidine dehydrogenase deficiency as a cause of fatal 5-Fluorouracil toxicity. Autopsy case Rep 8","DOI":"10.4322\/acr.2018.049"},{"key":"4740_CR6","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s00280-006-0392-5","volume":"60","author":"M Saif","year":"2007","unstructured":"Saif M, Ezzeldin H, Vance K et al (2007) DPYD* 2A mutation: the most common mutation associated with DPD deficiency. Cancer Chemother Pharmacol 60:503\u2013507","journal-title":"Cancer Chemother Pharmacol"},{"key":"4740_CR7","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1002\/cpt.911","volume":"103","author":"U Amstutz","year":"2018","unstructured":"Amstutz U, Henricks LM, Offer SM et al (2018) Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update. Clin Pharmacol Ther 103:210\u2013216","journal-title":"Clin Pharmacol Ther"},{"key":"4740_CR8","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1002\/cncr.30321","volume":"123","author":"WW Ma","year":"2017","unstructured":"Ma WW, Saif MW, El-Rayes BF et al (2017) Emergency use of uridine triacetate for the prevention and treatment of life\u2010threatening 5\u2010fluorouracil and capecitabine toxicity. Cancer 123:345\u2013356","journal-title":"Cancer"},{"key":"4740_CR9","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ejca.2019.09.028","volume":"124","author":"C Barin-Le Guellec","year":"2020","unstructured":"Barin-Le Guellec C, Lafay-Chebassier C, Ingrand I et al (2020) Toxicities associated with chemotherapy regimens containing a fluoropyrimidine: A real-life evaluation in France. Eur J Cancer 124:37\u201346","journal-title":"Eur J Cancer"},{"key":"4740_CR10","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1002\/onco.13967","volume":"26","author":"BB Sharma","year":"2021","unstructured":"Sharma BB, Rai K, Blunt H et al (2021) Pathogenic DPYD variants and treatment-related mortality in patients receiving fluoropyrimidine chemotherapy: a systematic review and meta-analysis. Oncologist 26:1008\u20131016","journal-title":"Oncologist"},{"key":"4740_CR11","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1002\/cpt.2667","volume":"112","author":"C White","year":"2022","unstructured":"White C, Scott RJ, Paul C et al (2022) Dihydropyrimidine dehydrogenase deficiency and implementation of upfront DPYD genotyping. Clin Pharmacol Ther 112:791\u2013802","journal-title":"Clin Pharmacol Ther"},{"key":"4740_CR12","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s43046-022-00117-4","volume":"34","author":"N Jose","year":"2022","unstructured":"Jose N, Joel A, Selvakumar RJ et al (2022) Diagnosis and management of 5-fluorouracil (5-FU)-induced acute leukoencephalopathy: Lessons learnt from a single-Centre case series. J Egypt Natl Cancer Inst 34:22","journal-title":"J Egypt Natl Cancer Inst"},{"key":"4740_CR13","doi-asserted-by":"publisher","first-page":"3207","DOI":"10.3390\/cancers14133207","volume":"14","author":"RB Diasio","year":"2022","unstructured":"Diasio RB, Offer SM (2022) Testing for Dihydropyrimidine Dehydrogenase Deficiency to Individualize 5-Fluorouracil Therapy. Cancers 14:3207","journal-title":"Cancers"},{"key":"4740_CR14","doi-asserted-by":"publisher","first-page":"4545","DOI":"10.1158\/1078-0432.CCR-16-0638","volume":"22","author":"G Ison","year":"2016","unstructured":"Ison G, Beaver JA, McGuinn WD Jr et al (2016) FDA Approval: Uridine Triacetate for the Treatment of Patients Following Fluorouracil or Capecitabine Overdose or Exhibiting Early-Onset Severe Toxicities Following Administration of These Drugs. Clin Cancer Res 22:4545\u20134549","journal-title":"Clin Cancer Res"},{"key":"4740_CR15","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1177\/1078155217732141","volume":"25","author":"M Zurayk","year":"2017","unstructured":"Zurayk M, Keung Y-K, Yu D et al (2017) Successful use of uridine triacetate (Vistogard) three weeks after capecitabine in a patient with homozygous dihydropyrimidine dehydrogenase mutation: A case report and review of the literature. J Oncol Pharm Pract 25:234\u2013238","journal-title":"J Oncol Pharm Pract"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-024-04740-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-024-04740-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-024-04740-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T05:08:46Z","timestamp":1737176926000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-024-04740-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,18]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["4740"],"URL":"https:\/\/doi.org\/10.1007\/s00280-024-04740-x","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,18]]},"assertion":[{"value":"23 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"26"}}